NCT03619837View on ClinicalTrials.gov

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

PHASE4CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

July 15, 2018

Primary Completion Date

December 21, 2019

Study Completion Date

August 13, 2020

Conditions
Hepatitis CTransplantation Disease Transmission
Interventions
DRUG

Sofosbuvir/Velpatasvir

Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.

DRUG

Sofosbuvir/Velpatasvir/Voxilaprevir

"Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks."

Trial Locations (6)

10032

Columbia University, New York

30309

Piedmont Research Institute, Atlanta

75246

Baylor University Medical Center - Dallas, Dallas

77030

Houston Methodist Hospital, Houston

80045

University of Colorado Denver, Aurora

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT03619837 - Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant | Biotech Hunter | Biotech Hunter